DR-332 Transcriptional evolution of lung cancer during progression and metastasis
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-332 Transcriptional evolution of lung cancer during progression and metastasis
Metastasis is the endpoint of tumorigenesis and is generally diagnosed at an untreatable stage. The molecular mechanisms underlying metastasis and …
DR-342 Telomere fusions in metastatic tumors
Telomeres protect our genomesfrom deterioration and instability. A key aspect of telomere biology is the occurrence of telomere fusions, which …
DR-316 Evaluating therapeutic efficacy of ERBB TKIs on patients harboring ERBB alterations
The EGFR family of receptor tyrosine kinases are frequently mutated (2-30% of cases in various cancers). Recently, samples harboring co-occurring …
DR-324 Identification of non-coding aberrations that drive cancer
The aim of this project is to perform pan-cancer and cancer-type specific analyses to gain insight into molecular aetiology, molecular …
DR-287 Comparing metastatic and primary breast tumours through the lens of integrated subtypes
Under DR-129, we have generated preliminary data that shows differences in the distribution of our genomic breast cancer subtypes between …
DR-321 Analyzing the correlations between gene expressions and mutations in breast cancer
Combination of several markers is necessary to effectively detect and diagnose cancer. To look for such fingerprints high-throughput multi-omics data …
DR-317 Integrated analysis of RNASeq and WGS data to target cancer with precision AI
The genomic mutational landscape observed in cancer cells represents impaired biological mechanisms, especially associated with replication stress response (RSR). Some …
DR-339 Analysis of the break rate profiles of metastatic solid tumours to investigate genomic enrichment of structural variants
We recently developed statistical framework, named Katdetectr, that robustly detects clustered somatic mutations (kataegis) in the DNA from cancer cells. …
DR-343 Chromosomal instability signatures and metastasis
Different factors can alter the DNA in a tumour cell such as chemical agents or the inability of the cells …
DR-283 The genetic basis of disease progression and drug resistance in advanced metastatic cancer
Metastasis is the primary cause of death in cancer and the mechanisms of cancer progression and metastasis are varied and …
DR-330 Enhancers driving oncogenes in ovarian cancer
Ovarian cancer is the most lethal gynecological cancer in the western world. It is typically diagnosed at a late stage …
DR-323 clusterCUP
Tumors are classified mainly by their cell of origin. Large cell neuroendocrine carcinomas are rare lung tumors and clinical studies …
Door WGS hebben we in de moleculaire diagnostiek op onze afdeling een stap gemaakt van de analyse van minder dan 100 genen naar circa 20.000 genen per patiënt. Dat levert ontzettend veel waardevolle informatie, niet alleen voor de patiënt van vandaag, maar ook voor de patiënt van de toekomst.